Perseus Proteomics Inc. [4882.T]
TOKYO, May 18 (Pulse News Wire) – Perseus Proteomics Inc. (4882.T) reported a revenue increase of approximately 12.5% for the fiscal year ended March 31, 2026, compared to the previous year.
Operating profit improved slightly to ¥-744 million from ¥-826 million. Research and development expenses stood at ¥287 million, down from ¥335 million last year, primarily due to costs associated with the PPMX-T003 ANKL phase I/II physician-led trial and foundational technology fees. The company also secured funding through a rights issue, exercising warrants, raising a total of ¥3.0 million.
Additionally, Perseus Proteomics received a grant of ¥100 million from the AMED pharmaceutical support program for its ongoing clinical trials. Looking ahead, the firm plans to continue advancing its pipeline projects, including the aggressive NK cell leukemia study for PPMX-T003, which saw an extension of its trial period until March 31, 2027. The company remains committed to developing innovative antibody technologies to contribute to global healthcare advancements.
🟡 Confidence: Standard AI-translated content.